A Single-Site, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Glucodynamic Effects of LY3192767 in Healthy Subjects

Trial Profile

A Single-Site, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Glucodynamic Effects of LY3192767 in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs LY 3192767 (Primary) ; Insulin glargine; Insulin peglispro
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 21 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top